All-trans retinoic acid-induced hypothalamus-pituitary-adrenal hyperactivity involves glucocorticoid receptor dysregulation

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Hu, P ^a   Liu, J ^a   Zhao, J ^a   Qi, X R ^a   Qi, C C ^a   Lucassen, P J ^b   Zhou, J N ^a  

^a University of Science and Technology of China   (China)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

all trans retinoic acid; corticotropin releasing hormone; depression; glucocorticoid receptor; hypothalamus pituitary adrenal axis; mifepristone (RU38486)

Indexed keywords

CORTICOSTERONE; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE; PROTEIN C FOS; RETINOIC ACID; CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID; HORMONE ANTAGONIST; HYDROCORTISONE; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CELL COUNT; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEPRESSION; DRUG TREATMENT FAILURE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERACTIVITY; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; MALE; MAZE TEST; NEGATIVE FEEDBACK; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; WEIGHT CHANGE; WESTERN BLOTTING; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; FEEDBACK SYSTEM; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; SECRETION (PROCESS); SIGNAL TRANSDUCTION;

ANIMALS; BEHAVIOR, ANIMAL; CORTICOSTERONE; CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; DEXAMETHASONE; FEEDBACK, PHYSIOLOGICAL; GLUCOCORTICOIDS; HORMONE ANTAGONISTS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MIFEPRISTONE; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PITUITARY-ADRENAL SYSTEM; RATS; RECEPTORS, GLUCOCORTICOID; RECEPTORS, RETINOIC ACID; SIGNAL TRANSDUCTION; TRETINOIN;

EID: 84890724046     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.98     Document Type: Article

References (78)

1. Tsukada M, Schroder M, Roos TC, Chandraratna RA, Reichert U, Merk HF et al. 13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. J Invest Dermatol 2000; 115: 321-327. (Pubitemid 30637206)
2. Durston AJ, Timmermans JP, Hage WJ, Hendriks HF, de Vries NJ, Heideveld M et al. Retinoic acid causes an anteroposterior transformation in the developing central nervous system. Nature 1989; 340: 140-144. (Pubitemid 19175364)
3. Maden M, Holder N. The involvement of retinoic acid in the development of the vertebrate central nervous system. Development 1991; Suppl 2: 87-94.
4. Maden M. Retinoic acid in the development, regeneration and maintenance of the nervous system. Nat Rev Neurosci 2007; 8: 755-765. (Pubitemid 47462115)
5. Jacobs S, Lie DC, DeCicco KL, Shi Y, DeLuca LM, Gage FH et al. Retinoic acid is required early during adult neurogenesis in the dentate gyrus. Proc Natl Acad Sci USA 2006; 103: 3902-3907. (Pubitemid 43376653)
6. Aoto J, Nam CI, Poon MM, Ting P, Chen L. Synaptic signaling by all-trans retinoic acid in homeostatic synaptic plasticity. Neuron 2008; 60: 308-320.
7. Wang HL, Zhang Z, Hintze M, Chen L. Decrease in calcium concentration triggers neuronal retinoic acid synthesis during homeostatic synaptic plasticity. J Neurosci 2011; 31: 17764-17771.
8. Bremner JD, Shearer KD, McCaffery PJ. Retinoic acid and affective disorders: the evidence for an association. J Clin Psychiatry 2012; 73: 37-50.
9. O'Reilly KC, Shumake J, Gonzalez-Lima F, Lane MA, Bailey SJ. Chronic administration of 13-cis-retinoic acid increases depression-related behavior in mice. Neuropsychopharmacology 2006; 31: 1919-1927.
10. McCance-Katz EF, Price LH. Depression associated with vitamin A intoxication. Psychosomatics 1992; 33: 117-118.
11. Wysowski DK, Pitts M, Beitz J. Depression and suicide in patients treated with isotretinoin. N Engl J Med 2001; 344: 460. (Pubitemid 32128686)
12. Chen XN, Meng QY, Bao AM, Swaab DF, Wang GH, Zhou JN. The involvement of retinoic acid receptor-alpha in corticotropin-releasing hormone gene expression and affective disorders. Biol Psychiatry 2009; 66: 832-839.
13. Qi XR, Zhao J, Liu J, Fang H, Swaab DF, Zhou JN. Abnormal retinoid and TrkB signaling in the prefrontal cortex in mood disorders. Cerebral Cortex 2013; doi:10.1093/cercor/bht203.
14. de Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci 2005; 6: 463-475. (Pubitemid 40769171)
15. Kageyama K, Suda T. Regulatory mechanisms underlying corticotropin- releasing factor gene expression in the hypothalamus. Endocr J 2009; 56: 335-344.
16. Cai L, Yan XB, Chen XN, Meng QY, Zhou JN. Chronic all-trans retinoic acid administration induced hyperactivity of HPA axis and behavioral changes in young rats. Eur Neuropsychopharmacol 2010; 20: 839-847.
17. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. Glucocorticoid feedback resistance. Trends Endocrinol Metab 1997; 8: 26-33. (Pubitemid 27090229)
18. Myers B, McKlveen JM, Herman JP. Neural regulation of the stress response: the many faces of feedback. Cell Mol Neurobiol 2012; 45: 292-298.
19. Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 2005; 4: 141-194. (Pubitemid 41114861)
20. Schmidt MV, Sterlemann V, Wagner K, Niederleitner B, Ganea K, Liebl C et al. Postnatal glucocorticoid excess due to pituitary glucocorticoid receptor deficiency: differential short-and long-term consequences. Endocrinology 2009; 150: 2709-2716.
21. Czeh B, Welt T, Fischer AK, Erhardt A, Schmitt W, Muller MB et al. Chronic psychosocial stress and concomitant repetitive transcranial magnetic stimulation: effects on stress hormone levels and adult hippocampal neurogenesis. Biol Psychiatry 2002; 52: 1057-1065. (Pubitemid 35379963)
22. Zobel AW, Yassouridis A, Frieboes RM, Holsboer F. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry 1999; 156: 949-951. (Pubitemid 29260354)
23. Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994; 60: 436-444. (Pubitemid 24284827)
24. Raadsheer FC, van Heerikhuize JJ, Lucassen PJ, Hoogendijk WJ, Tilders FJ, Swaab DF. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am J Psychiatry 1995; 152: 1372-1376.
25. Stenzel-Poore MP, Heinrichs SC, Rivest S, Koob GF, Vale WW. Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J Neurosci 1994; 14: 2579-2584. (Pubitemid 24140886)
26. Wang SS, Kamphuis W, Huitinga I, Zhou JN, Swaab DF. Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances. Mol Psychiatry 2008; 13: 786-799, 741.
27. Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord 2001; 62: 77-91. (Pubitemid 32126613)
28. Anacker C, Zunszain PA, Carvalho LA, Pariante CM. The glucocorticoid receptor: pivot of depression and of antidepressant treatment? Psychoneuroendocrinology 2011; 36: 415-425.
29. Barden N. Modulation of glucocorticoid receptor gene expression by antidepressant drugs. Pharmacopsychiatry 1996; 29: 12-22. (Pubitemid 26071333)
30. Pariante CM. Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids. Ann NY Acad Sci 2009; 1179: 144-152.
31. Nelson EB. Psychotic depression-beyond the antidepressant/antipsychotic combination. Curr Psychiatry Rep 2012; 14: 619-623.
32. Liu J, Bisschop PH, Eggels L, Foppen E, Fliers E, Zhou JN et al. Intrahypothalamic estradiol modulates hypothalamus-pituitary-adrenal-axis activity in female rats. Endocrinology 2012; 153: 3337-3344.
33. Shen H, Luo Y, Kuo CC, Deng X, Chang CF, Harvey BK et al. 9-Cis-retinoic acid reduces ischemic brain injury in rodents via bone morphogenetic protein. J Neurosci Res 2009; 87: 545-555.
34. Van Acker SA, Fluttert MF, Sibug RM, De Kloet ER. Intracerebroventricular administration of a glucocorticoid receptor antagonist enhances the cardiovascular responses to brief restraint stress. Eur J Pharmacol 2001; 430: 87-91. (Pubitemid 33042715)
35. Zhu H, Huang Q, Xu H, Niu L, Zhou JN. Antidepressant-like effects of sodium butyrate in combination with estrogen in rat forced swimming test: involvement of 5-HT(1A) receptors. Behav Brain Res 2009; 196: 200-206.
36. Andrews MH, Wood SA, Windle RJ, Lightman SL, Ingram CD. Acute glucocorticoid administration rapidly suppresses basal and stress-induced hypothalamopituitary-adrenal axis activity. Endocrinology 2012; 153: 200-211.
37. Loas G. Vulnerability to depression: a model centered on anhedonia. J Affect Disord 1996; 41: 39-53. (Pubitemid 26364975)
38. Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985; 14: 149-167. (Pubitemid 16239568)
39. Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2007; 2: 322-328. (Pubitemid 47040046)
40. Liu J, Hu P, Qi XR, Meng FT, Kalsbeek A, Zhou JN. Acute restraint stress increases intrahypothalamic oestradiol concentrations in conjunction with increased hypothalamic oestrogen receptor beta and aromatase mRNA expression in female rats. J Neuroendocrinol 2011; 23: 435-443.
41. Hu P, Oomen C, van Dam AM, Wester J, Zhou JN, Joels M et al. A single-day treatment with mifepristone is sufficient to normalize chronic glucocorticoid induced suppression of hippocampal cell proliferation. PLoS One 2012; 7: e46224.
42. Bao AM, Hestiantoro A, Van Someren EJ, Swaab DF, Zhou JN. Colocalization of corticotropin-releasing hormone and oestrogen receptor-alpha in the paraventricular nucleus of the hypothalamus in mood disorders. Brain 2005; 128: 1301-1313. (Pubitemid 40826184)
43. Stephanou A, Melino G, Knight RA, Annicchiarico-Petruzzelli M, Sarlis NJ, Finazzi-Agro A et al. Interleukin-6 and corticotrophin-releasing hormone mRNA are modulated during differentiation of human neuroblastoma cells. Neuropeptides 1992; 23: 45-49.
44. Yamamori E, Iwasaki Y, Taguchi T, Nishiyama M, Yoshida M, Asai M et al. Molecular mechanisms for corticotropin-releasing hormone gene repression by glucocorticoid in BE(2)C neuronal cell line. Mol Cell Endocrinol 2007; 264: 142-148. (Pubitemid 46097309)
45. Taniguchi Y, Iwasaki Y, Tsugita M, Nishiyama M, Taguchi T, Okazaki M et al. Glucocorticoid receptor-beta and receptor-gamma exert dominant negative effect on gene repression but not on gene induction. Endocrinology 2010; 151: 3204-3213.
46. Meijer OC, Kalkhoven E, van der Laan S, Steenbergen PJ, Houtman SH, Dijkmans TF et al. Steroid receptor coactivator-1 splice variants differentially affect corticosteroid receptor signaling. Endocrinology 2005; 146: 1438-1448. (Pubitemid 40289333)
47. van der Laan S, Lachize SB, Vreugdenhil E, de Kloet ER, Meijer OC. Nuclear receptor coregulators differentially modulate induction and glucocorticoid receptor-mediated repression of the corticotropin-releasing hormone gene. Endocrinology 2008; 149: 725-732. (Pubitemid 351159322)
48. Przybycien-Szymanska MM, Mott NN, Pak TR. Alcohol dysregulates corticotropinreleasing-hormone (CRH) promoter activity by interfering with the negative glucocorticoid response element (nGRE). PLoS One 2011; 6: e26647.
49. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408. (Pubitemid 34164012)
50. Hazen PG, Carney JF, Walker AE, Stewart JJ. Depression-a side effect of 13-cisretinoic acid therapy. J Am Acad Dermatol 1983; 9: 278-279.
51. Crandall J, Sakai Y, Zhang J, Koul O, Mineur Y, Crusio WE et al. 13-cis-retinoic acid suppresses hippocampal cell division and hippocampal-dependent learning in mice. Proc Natl Acad Sci USA 2004; 101: 5111-5116. (Pubitemid 38469211)
52. Herman JP, Ostrander MM, Mueller NK, Figueiredo H. Limbic system mechanisms of stress regulation: hypothalamo-pituitary-adrenocortical axis. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1201-1213. (Pubitemid 41674635)
53. Kovacs KJ, Mezey E. Dexamethasone inhibits corticotropin-releasing factor gene expression in the rat paraventricular nucleus. Neuroendocrinology 1987; 46: 365-368. (Pubitemid 17144487)
54. Sawchenko PE. Evidence for a local site of action for glucocorticoids in inhibiting CRF and vasopressin expression in the paraventricular nucleus. Brain Res 1987; 403: 213-223.
55. Di S, Malcher-Lopes R, Halmos KC, Tasker JG. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci 2003; 23: 4850-4857. (Pubitemid 36793211)
56. Malkoski SP, Dorin RI. Composite glucocorticoid regulation at a functionally defined negative glucocorticoid response element of the human corticotropinreleasing hormone gene. Mol Endocrinol 1999; 13: 1629-1644. (Pubitemid 30645269)
57. Gutierrez-Mecinas M, Trollope AF, Collins A, Morfett H, Hesketh SA, Kersante F et al. Long-lasting behavioral responses to stress involve a direct interaction of glucocorticoid receptors with ERK1/2-MSK1-Elk-1 signaling. Proc Natl Acad Sci USA 2011; 108: 13806-13811.
58. Xu L, Holscher C, Anwyl R, Rowan MJ. Glucocorticoid receptor and protein/RNA synthesis-dependent mechanisms underlie the control of synaptic plasticity by stress. Proc Natl Acad Sci USA 1998; 95: 3204-3208. (Pubitemid 28135880)
59. Qi XR, Kamphuis W, Wang S, Wang Q, Lucassen PJ, Zhou JN et al. Aberrant stress hormone receptor balance in the human prefrontal cortex and hypothalamic paraventricular nucleus of depressed patients. Psychoneuroendocrinology 2013; 38: 863-870.
60. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001; 49: 391-404. (Pubitemid 32234301)
61. Jeanneteau FD, Lambert WM, Ismaili N, Bath KG, Lee FS, Garabedian MJ et al. BDNF and glucocorticoids regulate corticotrophin-releasing hormone (CRH) homeostasis in the hypothalamus. Proc Natl Acad Sci USA 2012; 109: 1305-1310.
62. Surjit M, Ganti KP, Mukherji A, Ye T, Hua G, Metzger D et al. Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 2011; 145: 224-241.
63. Toth K, Sarang Z, Scholtz B, Brazda P, Ghyselinck N, Chambon P et al. Retinoids enhance glucocorticoid-induced apoptosis of T cells by facilitating glucocorticoid receptor-mediated transcription. Cell Death Differ 2011; 18: 783-792.
64. Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin J et al. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 1990; 62: 1205-1215.
65. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 2001; 21: 516-521. (Pubitemid 32937434)
66. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012; 97: 2039-2049.
67. Blasey CM, Block TS, Belanoff JK, Roe RL. Efficacy and safety of mifepristone for the treatment of psychotic depression. J Clin Psychopharmacol 2011; 31: 436-440.
68. Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 2006; 31: 628-636. (Pubitemid 43276978)
69. van der Lely AJ, Foeken K, van der Mast RC, Lamberts SW. Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann Intern Med 1991; 114: 143-144.
70. Watson S, Gallagher P, Porter RJ, Smith MS, Herron LJ, Bulmer S et al. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Biol Psychiatry 2012; 72: 943-949.
71. Oomen CA, Mayer JL, de Kloet ER, Joels M, Lucassen PJ. Brief treatment with the glucocorticoid receptor antagonist mifepristone normalizes the reduction in neurogenesis after chronic stress. Eur J Neurosci 2007; 26: 3395-3401. (Pubitemid 350243543)
72. Wulsin AC, Herman JP, Solomon MB. Mifepristone decreases depression-like behavior and modulates neuroendocrine and central hypothalamic- pituitaryadrenocortical axis responsiveness to stress. Psychoneuroendocrinology 2010; 35: 1100-1112.
73. van Haarst AD, Oitzl MS, de Kloet ER. Facilitation of feedback inhibition through blockade of glucocorticoid receptors in the hippocampus. Neurochem Res 1997; 22: 1323-1328. (Pubitemid 27461131)
74. Schulz M, Eggert M, Baniahmad A, Dostert A, Heinzel T, Renkawitz R. RU486-induced glucocorticoid receptor agonism is controlled by the receptor N terminus and by corepressor binding. J Biol Chem 2002; 277: 26238-26243. (Pubitemid 34967112)
75. Rogatsky I, Hittelman AB, Pearce D, Garabedian MJ. Distinct glucocorticoid receptor transcriptional regulatory surfaces mediate the cytotoxic and cytostatic effects of glucocorticoids. Mol Cell Biol 1999; 19: 5036-5049. (Pubitemid 29289542)
76. Pandit S, Geissler W, Harris G, Sitlani A. Allosteric effects of dexamethasone and RU486 on glucocorticoid receptor-DNA interactions. J Biol Chem 2002; 277: 1538-1543. (Pubitemid 34968911)
77. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985; 61: 536-540. (Pubitemid 15243969)
78. Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med 1997; 48: 129-156. (Pubitemid 27101820)